CoaguSense is a medical device company that has developed an anticoagulation monitoring apparatus for individuals at risk for thrombosis, an adverse blood clot formation that can block blood vessels leading to heart attack or stroke. Currently, a patient’s susceptibility to thrombosis is determined by measuring the individual’s blood clotting time with a prothrombin time test, which is a biochemical method of measuring the amount of time it takes a sample of blood to clot. The company has used its proprietary micro opto-mechanical technology to develop the first portable prothrombin time test device that can directly detect the clot formation. Older technology uses secondary means of detecting the clot formation such as monitoring current across the sample or pressure. The company’s methodology provides a faster, more reliable and cost effective means of determining thrombosis risk, particularly with the expansion of medicare coverage that now includes patient self-testing.